Copyright Reports & Markets. All rights reserved.

Global Huntingtons Disease Therapeutics Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Huntingtons Disease Therapeutics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Huntingtons Disease Therapeutics Market Size Growth Rate by Product
      • 1.4.2 Antidopaminergics
      • 1.4.3 Anticonvulsants
      • 1.4.4 Antipsychotics
      • 1.4.5 Antidepressants
    • 1.5 Market by End User
      • 1.5.1 Global Huntingtons Disease Therapeutics Market Size Growth Rate by End User
      • 1.5.2 Hosptial
      • 1.5.3 Clinic
      • 1.5.4 Research
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Huntingtons Disease Therapeutics Market Size
      • 2.1.1 Global Huntingtons Disease Therapeutics Revenue 2014-2025
      • 2.1.2 Global Huntingtons Disease Therapeutics Sales 2014-2025
    • 2.2 Huntingtons Disease Therapeutics Growth Rate by Regions
      • 2.2.1 Global Huntingtons Disease Therapeutics Sales by Regions
      • 2.2.2 Global Huntingtons Disease Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Huntingtons Disease Therapeutics Sales by Manufacturers
      • 3.1.1 Huntingtons Disease Therapeutics Sales by Manufacturers
      • 3.1.2 Huntingtons Disease Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Huntingtons Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Huntingtons Disease Therapeutics Revenue by Manufacturers
      • 3.2.1 Huntingtons Disease Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Huntingtons Disease Therapeutics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Huntingtons Disease Therapeutics Price by Manufacturers
    • 3.4 Huntingtons Disease Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Huntingtons Disease Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Huntingtons Disease Therapeutics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Huntingtons Disease Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Huntingtons Disease Therapeutics Sales by Product
    • 4.2 Global Huntingtons Disease Therapeutics Revenue by Product
    • 4.3 Huntingtons Disease Therapeutics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Huntingtons Disease Therapeutics Breakdown Data by End User

    6 North America

    • 6.1 North America Huntingtons Disease Therapeutics by Countries
      • 6.1.1 North America Huntingtons Disease Therapeutics Sales by Countries
      • 6.1.2 North America Huntingtons Disease Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Huntingtons Disease Therapeutics by Product
    • 6.3 North America Huntingtons Disease Therapeutics by End User

    7 Europe

    • 7.1 Europe Huntingtons Disease Therapeutics by Countries
      • 7.1.1 Europe Huntingtons Disease Therapeutics Sales by Countries
      • 7.1.2 Europe Huntingtons Disease Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Huntingtons Disease Therapeutics by Product
    • 7.3 Europe Huntingtons Disease Therapeutics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Huntingtons Disease Therapeutics by Countries
      • 8.1.1 Asia Pacific Huntingtons Disease Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Huntingtons Disease Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Huntingtons Disease Therapeutics by Product
    • 8.3 Asia Pacific Huntingtons Disease Therapeutics by End User

    9 Central & South America

    • 9.1 Central & South America Huntingtons Disease Therapeutics by Countries
      • 9.1.1 Central & South America Huntingtons Disease Therapeutics Sales by Countries
      • 9.1.2 Central & South America Huntingtons Disease Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Huntingtons Disease Therapeutics by Product
    • 9.3 Central & South America Huntingtons Disease Therapeutics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Huntingtons Disease Therapeutics by Countries
      • 10.1.1 Middle East and Africa Huntingtons Disease Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Huntingtons Disease Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Huntingtons Disease Therapeutics by Product
    • 10.3 Middle East and Africa Huntingtons Disease Therapeutics by End User

    11 Company Profiles

    • 11.1 Auspex Pharmaceuticals
      • 11.1.1 Auspex Pharmaceuticals Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Auspex Pharmaceuticals Huntingtons Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Auspex Pharmaceuticals Huntingtons Disease Therapeutics Products Offered
      • 11.1.5 Auspex Pharmaceuticals Recent Development
    • 11.2 Alnylam Pharmaceuticals
      • 11.2.1 Alnylam Pharmaceuticals Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Alnylam Pharmaceuticals Huntingtons Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Alnylam Pharmaceuticals Huntingtons Disease Therapeutics Products Offered
      • 11.2.5 Alnylam Pharmaceuticals Recent Development
    • 11.3 Intellect Neurosciences Incorporation
      • 11.3.1 Intellect Neurosciences Incorporation Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Intellect Neurosciences Incorporation Huntingtons Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Intellect Neurosciences Incorporation Huntingtons Disease Therapeutics Products Offered
      • 11.3.5 Intellect Neurosciences Incorporation Recent Development
    • 11.4 H. Lundbeck
      • 11.4.1 H. Lundbeck Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 H. Lundbeck Huntingtons Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 H. Lundbeck Huntingtons Disease Therapeutics Products Offered
      • 11.4.5 H. Lundbeck Recent Development
    • 11.5 Prana Biotechnology Limited
      • 11.5.1 Prana Biotechnology Limited Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Prana Biotechnology Limited Huntingtons Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Prana Biotechnology Limited Huntingtons Disease Therapeutics Products Offered
      • 11.5.5 Prana Biotechnology Limited Recent Development
    • 11.6 Raptor Pharmaceuticals
      • 11.6.1 Raptor Pharmaceuticals Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Raptor Pharmaceuticals Huntingtons Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Raptor Pharmaceuticals Huntingtons Disease Therapeutics Products Offered
      • 11.6.5 Raptor Pharmaceuticals Recent Development
    • 11.7 Sangamo Biosciences
      • 11.7.1 Sangamo Biosciences Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Sangamo Biosciences Huntingtons Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Sangamo Biosciences Huntingtons Disease Therapeutics Products Offered
      • 11.7.5 Sangamo Biosciences Recent Development
    • 11.8 Teva Pharmaceutical Industries
      • 11.8.1 Teva Pharmaceutical Industries Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Teva Pharmaceutical Industries Huntingtons Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Teva Pharmaceutical Industries Huntingtons Disease Therapeutics Products Offered
      • 11.8.5 Teva Pharmaceutical Industries Recent Development
    • 11.9 Trophos SA
      • 11.9.1 Trophos SA Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Trophos SA Huntingtons Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Trophos SA Huntingtons Disease Therapeutics Products Offered
      • 11.9.5 Trophos SA Recent Development
    • 11.10 Valeant Pharmaceuticals International
      • 11.10.1 Valeant Pharmaceuticals International Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Valeant Pharmaceuticals International Huntingtons Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Valeant Pharmaceuticals International Huntingtons Disease Therapeutics Products Offered
      • 11.10.5 Valeant Pharmaceuticals International Recent Development
    • 11.11 Vertex Pharmaceuticals
    • 11.12 Roche

    12 Future Forecast

    • 12.1 Huntingtons Disease Therapeutics Market Forecast by Regions
      • 12.1.1 Global Huntingtons Disease Therapeutics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Huntingtons Disease Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.2 Huntingtons Disease Therapeutics Market Forecast by Product
      • 12.2.1 Global Huntingtons Disease Therapeutics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Huntingtons Disease Therapeutics Revenue Forecast by Product 2019-2025
    • 12.3 Huntingtons Disease Therapeutics Market Forecast by End User
    • 12.4 North America Huntingtons Disease Therapeutics Forecast
    • 12.5 Europe Huntingtons Disease Therapeutics Forecast
    • 12.6 Asia Pacific Huntingtons Disease Therapeutics Forecast
    • 12.7 Central & South America Huntingtons Disease Therapeutics Forecast
    • 12.8 Middle East and Africa Huntingtons Disease Therapeutics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Huntingtons Disease Therapeutics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Huntington's disease is an inherited disease that causes degeneration of nerve cells in the central nervous system (CNS). The disease has a broad impact on functional abilities of the human and usually results in movement and thinking disabilities. Most people with Huntington's disease develop signs and symptoms in their age of 30 to 40. When disease begins before age 20, the condition is known as juvenile Huntington's disease.
      The global Huntingtons Disease Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Huntingtons Disease Therapeutics market based on company, product type, end user and key regions.

      This report studies the global market size of Huntingtons Disease Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Huntingtons Disease Therapeutics in these regions.
      This research report categorizes the global Huntingtons Disease Therapeutics market by top players/brands, region, type and end user. This report also studies the global Huntingtons Disease Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Auspex Pharmaceuticals
      Alnylam Pharmaceuticals
      Intellect Neurosciences Incorporation
      H. Lundbeck
      Prana Biotechnology Limited
      Raptor Pharmaceuticals
      Sangamo Biosciences
      Teva Pharmaceutical Industries
      Trophos SA
      Valeant Pharmaceuticals International
      Vertex Pharmaceuticals
      Roche

      Market size by Product
      Antidopaminergics
      Anticonvulsants
      Antipsychotics
      Antidepressants
      Market size by End User
      Hosptial
      Clinic
      Research

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Huntingtons Disease Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Huntingtons Disease Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Huntingtons Disease Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Huntingtons Disease Therapeutics submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Huntingtons Disease Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Huntingtons Disease Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now